L · 0R29.L · MEDICAL - DEVICES
Intuitive Surgical, Inc. (0R29.L) intrinsic value and stock valuation
$405.33as of 2026-11-21 · Mkt cap 149.27B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Intuitive Surgical, Inc. DCF and intrinsic value
InvestorsCraft values 0R29.L with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from 0R29.L’s statements →
Intuitive Surgical, Inc. Graham Number
Graham Number: $95.14d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $10.1B | $8.35B | $7.12B | $6.22B | $5.71B |
| Operating income | $2.95B | $2.35B | $1.77B | $1.58B | $1.82B |
| Net income | $2.86B | $2.32B | $1.8B | $1.32B | $1.7B |
| EPSd | $7.87M | $6.42M | $5.03M | $3.65M | $4.66M |
| Operating cash flow | $3.03B | $2.42B | $1.81B | $1.49B | $2.09B |
| Capital expenditure | -$-539.8M | -$-1.11B | -$-1.06B | -$-532.4M | -$-353.5M |
| Free cash flow | $2.49B | $1.3B | $749.6M | $958.4M | $1.74B |
| Total assets | $20.6B | $18.8B | $15.4B | $13B | $13.6B |
| Total debt | $170.9M | $146M | $89.8M | $93.8M | $87M |
| Net debt | -$-3.2B | -$-1.88B | -$-2.66B | -$-1.49B | -$-1.2B |
| Total equity | $17.9B | $16.5B | $13.4B | $11.1B | $12B |
| Cash and short-term investments | $5.93B | $4.01B | $5.22B | $4.12B | $4.2B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $10.1B | $8.35B | $7.12B | $6.22B | $5.71B |
| Cost of revenue | $3.41B | $2.72B | $2.39B | $2.03B | $1.77B |
| Gross profit | $6.66B | $5.63B | $4.73B | $4.19B | $3.94B |
| Research and development expenses | $1.31B | $1.15B | $998.8M | $876.3M | $659.9M |
| Selling, general and administrative expenses | $2.39B | $2.14B | $1.96B | $1.73B | $1.46B |
| Other expenses | $13.2M | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $3.71B | $3.29B | $2.96B | $2.61B | $2.12B |
| Cost and expenses | $7.12B | -$-6B | $5.36B | $4.65B | $3.89B |
| Interest income | $365.9M | $0.00 | $0.00 | $106M | $80.8M |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $625.1M | $455.7M | $402.2M | $380.4M | $317M |
| Ebitda | $3.57B | $3.13B | $2.17B | $1.99B | $2.14B |
| Operating income | $2.95B | $2.35B | $1.77B | $1.58B | $1.82B |
| Total other income/expenses, net | $365.9M | $324.9M | $192.1M | $29.7M | $69.3M |
| Income before tax | $3.31B | $2.67B | $1.96B | $1.61B | $1.89B |
| Income tax expense | $434.8M | $336.3M | $141.6M | $262.4M | $162.2M |
| Net income | $2.86B | $2.32B | $1.8B | $1.32B | $1.7B |
| Weighted average shares outstanding | $356.9M | $355.2M | $351.2M | $355.7M | $356.1M |
| Weighted average diluted shares outstanding | $362.7M | $362M | $357.4M | $362M | $365.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $5.93B | $4.01B | $5.22B | $4.12B | $4.2B |
| Net receivables | $1.63B | $1.36B | $1.27B | $1.07B | $893M |
| Inventory | $1.84B | $1.49B | $1.22B | $893.2M | $587.1M |
| Total current assets | $9.78B | $7.11B | $7.89B | $6.25B | $5.84B |
| Property, plant and equipment, net | $5.49B | $4.78B | $3.62B | $2.46B | $1.95B |
| Goodwill and intangible assets | $381.4M | $370.5M | $387.8M | $398.3M | $414.1M |
| Long-term investments | $3.3B | $5.06B | $2.19B | $2.98B | $4.69B |
| Total non-current assets | $10.9B | $11.7B | $7.55B | $6.72B | $7.71B |
| Total assets | $20.6B | $18.8B | $15.4B | $13B | $13.6B |
| Accounts payable | $255.1M | $193.4M | $188.7M | $147M | $121.2M |
| Short-term debt | $39M | $33.5M | $25.3M | $24.2M | $20.4M |
| Deferred revenue | $506.7M | $468.8M | $0.00 | $397.3M | $377.2M |
| Total current liabilities | $2.01B | $1.75B | $1.66B | $1.42B | $1.15B |
| Long-term debt | $131.9M | $112.5M | $64.5M | $69.6M | $66.6M |
| Deferred revenue, non-current | $91.4M | $54.1M | $0.00 | $41M | $36.8M |
| Total non-current liabilities | $683.3M | $563.7M | $467.6M | $439.3M | $453.7M |
| Capital lease obligations | $131.9M | $112.5M | $89.8M | $93.8M | $87M |
| Total liabilities | $2.69B | $2.31B | $2.04B | $1.86B | $1.6B |
| Common stock | $400K | $400K | $400K | $400K | $400K |
| Retained earnings | $7.01B | $6.8B | $4.74B | $3.5B | $4.76B |
| Accumulated other comprehensive income (loss) | $43.3M | -$-51.3M | -$-12.2M | -$-162.5M | -$-24.2M |
| Total equity | $17.9B | $16.5B | $13.4B | $11.1B | $12B |
| Total investments | $5.87B | $7.05B | $4.67B | $5.52B | $7.61B |
| Total debt | $170.9M | $146M | $89.8M | $93.8M | $87M |
| Net debt | -$-3.2B | -$-1.88B | -$-2.66B | -$-1.49B | -$-1.2B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $2.86B | $2.32B | $1.8B | $1.32B | $1.7B |
| Depreciation and amortization | $625.1M | $455.7M | $435.2M | $380.4M | $317M |
| Stock-based compensation | $0.00 | $0.00 | $598.2M | $516.5M | $456.8M |
| Change in working capital | -$-1.27B | -$-919.3M | -$-872.7M | -$-619.1M | -$-368.1M |
| Accounts receivable | -$-301.7M | -$-95.9M | -$-186.3M | -$-159.3M | -$-142.3M |
| Inventory | -$-1.06B | -$-830M | -$-712.5M | -$-546.6M | -$-256M |
| Accounts payable | $57.9M | -$-400K | $41.7M | $21.3M | $36M |
| Net cash provided by operating activities | $3.03B | $2.42B | $1.81B | $1.49B | $2.09B |
| Investments in property, plant and equipment | -$-539.8M | -$-1.11B | -$-1.06B | -$-532.4M | -$-353.5M |
| Acquisitions, net | $0.00 | -$-1M | -$-8.9M | -$-12.8M | -$-8.7M |
| Net cash used for investing activities | $665.8M | -$-3.27B | -$-360.1M | $1.37B | -$-2.46B |
| Common stock issued | $350.3M | $429.4M | $0.00 | $233.8M | $276.5M |
| Common stock repurchased | -$-2.3B | $0.00 | -$-581M | -$-2.61B | -$-211.6M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-2.36B | $150.9M | -$-287.6M | -$-2.57B | $43M |
| Net change in cash | $1.34B | $0.00 | $1.17B | $290.3M | -$-331.7M |
| Cash at end of period | $3.37B | $2.03B | $2.77B | $1.58B | $1.29B |
| Operating cash flow | $3.03B | $2.42B | $1.81B | $1.49B | $2.09B |
| Capital expenditure | -$-539.8M | -$-1.11B | -$-1.06B | -$-532.4M | -$-353.5M |
| Free cash flow | $2.49B | $1.3B | $749.6M | $958.4M | $1.74B |
Line items
Line items
Line items
About Intuitive Surgical, Inc.
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
- CEO
- David J. Rosa
- Employees
- 15.64K
- Beta
- 1.51
Explore
Frequently asked questions
What is the intrinsic value of Intuitive Surgical, Inc. (0R29.L)?
InvestorsCraft does not currently publish an intrinsic value for 0R29.L. How the IC value is calculated.
Is 0R29.L undervalued?
InvestorsCraft does not publish an undervaluation signal for 0R29.L at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.